ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "prevention"

  • Abstract Number: 2414 • ACR Convergence 2024

    A Retrospective Comparative Analysis of Cardiovascular Risk Factors, Atherosclerotic Cardiovascular Disease and Statin Use as Secondary Prevention in a Cohort of Patients with Systemic Lupus Erythematosus versus Without Rheumatological Disease from a Single-Center Patient Registry

    Alma Aveytia Camacho1, Rakesh Gullapelli2, Vineetha Philip3, Soudabeh Daliri1, Ruba Memon4, Helene DiGregorio2, Lily Romero Karam2, Kanika Monga3, Eleonora Avenatti2, Khurram Nasir2 and Myriam Guevara1, 1Houston Methodist, Houston, TX, 2Houston Methodist Hospital, Houston, TX, 3Houston Methodist Hospital, Sugar Land, TX, 4Houston Methodist, Missouri City, TX

    Background/Purpose: Patients with systemic lupus erythematosus (SLE) have increased prevalence of cardiovascular risk factors (RFs), which predispose to higher risk of premature atherosclerotic cardiovascular disease…
  • Abstract Number: 0701 • ACR Convergence 2024

    Diagnostic Performances of Vascular Biomarkers Soluble Fms-like Tyrosine Kinase (sFlt-1) and Placental Growth Factor (PlGF) in Scleroderma Renal Crisis: A Case Control Study

    Aïcha Kante1, Paul Legendre2, Bérangère Joly3, bertrand Dunogue4, Alexandre Hertig5, Benjamin Terrier6, Elodie Massolin7, Felix Ackermann8, Luc Mouthon4, Jean Guibourdenche9 and Benjamin Chaigne10, 1Department of internal medicine, Centre de Compétence Maladies Rares autoimmunes et inflammatoires, Université Paris Cité, Paris, Ile-de-France, France, 2Service immunologie clinique, Centre hospitalier du Mans, Le Mans, France, Le Mans, 3Service d'Hématologie Biologique, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris (APHP.Nord), Université Paris Cité, Paris, Ile-de-France, France, 4Service de Médecine Interne, Centre de Référence Maladies Systémiques Autoimmunes et Autoinflammatoires Rares d'Ile de France de l’Est et de l’Ouest, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, 5Department of Nephrology, Hôpital Foch, Suresnes, France, Suresnes, Ile-de-France, France, 6Service de Médecine interne, Hôpital Cochin, AP-HP, Paris, Ile-de-France, France, 7UF d'Hormonologie, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (APHP), Paris, Paris, Ile-de-France, France, 8Department of Internal Medicine, Foch Hospital, Suresnes, France., Suresnes, France, 9APHP-CUP, Hôpital Cochin, F-75014 Paris, Université Paris Cité, Paris, Ile-de-France, France, 10Service de Médecine Interne, Centre de Référence Maladies Systémiques Autoimmunes et Autoinflammatoires Rares d'Ile de France de l’Est et de l’Ouest, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, Ile-de-France, France

    Background/Purpose: Scleroderma renal crisis (SRC) is a major vascular complication of systemic sclerosis (SSc), associated with high morbidity and mortality. Few biomarkers are available to predict…
  • Abstract Number: 2433 • ACR Convergence 2024

    Sequential Pneumococcal Vaccination in SLE: Immunogenicity, Side Effects and Comparison with PPSV23 Vaccination

    Rudrarpan Chatterjee1, Sai Yasaswini Kommaraju2, Shincy MR3 and Amita Aggarwal4, 1Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow., Lucknow, Uttar Pradesh, India, 2Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India, 3Central research lab, Kampewgowda Institute of Medical Sciences, Bengaluru, 4Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, Lucknow, Uttar Pradesh, India

    Background/Purpose: SLE patients have increased risk of invasive pneumococcal disease due to immune dysregulation and drugs used in these patients. EULAR 2019 recommendation suggest sequential…
  • Abstract Number: 0844 • ACR Convergence 2024

    Effectiveness and Safety of the Recombinant Zoster Vaccine in Patients ≥18 Years of Age with Systemic Lupus Erythematosus or Multiple Sclerosis

    Sheryl Kluberg1, Sophie E. Mayer2, O’Mareen Spence3, Driss Oraichi4, Harry Seifert4, Omar Ali3, Huifeng Yun4, Andrew L. Simon5, Jenice S. Ko6, Caroline Hugh7, Meg Her7, Kathleen Shattuck7, Richard Platt8, Aziza Jamal-Allial9, Djeneba Audrey DJIBO10, Kimberly Daniels11, Qianli Ma12, Cheryl N McMahill-Walraven10, Rachel P. Ogilvie13, Kristin Palmsten14, Mano Selvan15, Najat Ziyadeh16, Alexis Ogdie17 and Michael George18, 1Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA, 2Harvard Pilgrim Health Care Institute, Durham, 3GSK, Rockville, 4GSK, Rockville, MD, 5Harvard Pilgrim Healthcare Institute, Boston, MA, 6Harvard Pilgrim Health Care Ins􀆟tute, Boston, MA, 7Harvard Pilgrim Health Care Institute, Boston, MA, 8Harvard Pilgrim Health Care Institute / Harvard Medical School, Boston, MA, 9Carelon Research, Elevance Health, Newton, 10CVS Health, Blue Bell, 11Carelon Research, Elevance Health, Wilmington, 12Humana Healthcare Research, Inc., Louisville, 13Optum, Boston, MA, 14HealthPartners Institute, Minneapolis, 15Humana Healthcare Research, Sugar Land, Texas, 16Optum, Baltimore, MD, 17Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 18University of Pennsylvania, Philadelphia, PA

    Background/Purpose: The recombinant zoster vaccine (RZV) is US Food and Drug Administration-approved for the prevention of herpes zoster (HZ, shingles) in adults ≥50 years, and…
  • Abstract Number: 2588 • ACR Convergence 2024

    Examining the Influence of Socioeconomic Status on Osteoarthritis Prevalence and Risk Factors Among New York Residents

    Titilayo Adeniran1, David Cecil2 and Ahinee Amamoo3, 1Hospital for Special Surgery (HSS), New York, NY, 2Samford University, Birmingham, 3Samford University, Birmingham, AL

    Background/Purpose: Osteoarthritis (OA) is a chronic, progressive condition affecting the musculoskeletal system, significantly impacting the quality of life and mobility of millions worldwide. It is…
  • Abstract Number: 0209 • ACR Convergence 2023

    Safety of Bivalent SARS-CoV-2 Vaccines as a Second Booster Dose in Arthritis Patients on Immunosuppressive Therapies

    Hilde Ørbo1, Ingrid Jyssum1, Anne Therese Tveter1, Ingrid Christensen1, Joseph Sexton1, Kristin Hammersbøen Bjørlykke2, Grete B. Kro3, Tore Kvien1, Gunnveig Grødeland4, Ludvig A. Munthe5, Siri Mjaaland6, John Torgils Vaage5, Espen Haavardsholm1, Kristin Kaasen Jørgensen2, Sella Provan7, Silje Watterdal Syversen1 and Guro Goll1, 1Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, 2Department of Gastroenterology, Akershus University Hospital, Oslo, Norway, 3Department of Microbiology, Oslo University Hospital, Oslo, Norway, 4Department of Immunology, Oslo University Hospital, Oslo, Norway, 5Department of Immunology, Oslo University Hospital, Oslo, Norway, 6Norwegian Institute of Public Health, Oslo, Norway, 7Diakonhjemmet Hospital, Oslo, Norway

    Background/Purpose: Safety and efficacy of updated bivalent vaccines, containing both the original vaccine variant of SARS-CoV-2 Spike and either Omicron variants BA.1 or BA.4/5, are…
  • Abstract Number: 1801 • ACR Convergence 2023

    Tixagevimab/Cilgavimab for the Prevention of COVID-19 in Vaccine-refractory Patients with Autoimmune Diseases: A Prospective Cohort Study

    Ioanna Minopoulou1, Koray Tascilar2, Giulia Corte1, Melek Yalcin Mutlu1, Katja Schmidt2, Daniela Bohr1, Fabian Hartmann2, Bernhard Manger2, Arnd Kleyer3, David Simon1, Thomas Harrer2, Georg Schett4 and Filippo Fagni1, 1Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg & Universitätsklinikum Erlangen, Department of Internal Medicine 3 - Rheumatology and Immunology / Deutsches Zentrum Immuntherapie, Erlangen, Germany, 2Department of Internal Medicine 3, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, 3University Hospital Erlangen, Erlangen, Germany, 4Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany

    Background/Purpose: Patients with immune-mediated inflammatory diseases (IMIDs) and particularly those treated with B-cell-depleting agents frequently fail to develop humoral responses to SARS-CoV-2 vaccinations and have…
  • Abstract Number: 0217 • ACR Convergence 2023

    Safety and Efficacy of Tixagevimab/Cilgavimab (Evusheld) in Autoimmune Inflammatory Rheumatic Disease Patients – a Prospective Multicenter Open-label Study

    Tali Eviatar1, Victoria Furer2, Ilana Kaufman3, David levartovsky2, Ofir Elalouf2, Devy Zisman4, Tal Gazitt5, Amir Haddad4, Muna Elias6, Joy Feld7, Alexandra Balbir-Gurman8, Yolanda Braun Moscovici9, Sara Pel10, sharon Nevo11, Daphna Paran2 and Ori Elkayam2, 1Tel Aviv Sourasky Medical center, Ramat Gan, Israel, 2Tel Aviv Medical Center, Tel Aviv, Israel, 3Tel Aviv Medical Center, Petah-Tikva, Israel, 4Carmel Medical Center, Haifa, Israel, 5Carmel Hospital, Haifa, Israel, 6rheumatology unit, Haifa, Israel, 7Carmel and Zvulun Medical Centre, Haifa, Israel, 8Rheumatology Institute, Rambam Health Care Campus and Rappaport Faculty of |Medicine, Technion, Haifa, Israel, 9Rambam Heath Care Campus, Haifa, Israel, 10Tel Aviv Medical Center, Modiin, Israel, 11Tel Aviv Sourasky Medical Center, Givataim, Israel

    Background/Purpose: Autoimmune inflammatory rheumatic disease (AIIRD) patients treated with rituximab (RTX) are at risk for severe COVID19 infection, and a blunted humoral response to SARS-CoV-2…
  • Abstract Number: 1848 • ACR Convergence 2023

    Demographic and Clinical Factors Associated with HPV Vaccination in Young Adults with Rheumatic Disease

    Caroline Siegel1, Lauren Robinson1, Deanna Jannat-Khah1, Avi Mikhaylov1, Nancy Pan1 and Lisa Sammaritano2, 1Hospital for Special Surgery, New York, NY, 2Hospital for Special Surgery, Weill Cornell Medicine, New York, NY

    Background/Purpose: The HPV vaccine is safe and immunogenic in RD patients but uptake is suboptimal. We aimed to evaluate factors associated with HPV vaccination in…
  • Abstract Number: 0219 • ACR Convergence 2023

    Safety and Efficacy of Pre-Exposure Prophylaxis with Tixagevimab/Cilgavimab (Evusheld) in Patients with Autoimmune Diseases and Renal Involvement Who Received Rituximab

    Savino Sciascia1, MARIA LETIZIA RILAT2, ROBERTA FENOGLIO2, SILVIA GRAZIETTA FODDAI3, MASSIMO RADIN3, IRENE CECCHI3, giacoma cinnirella2, paola crosasso2, maria gabriella guidetti2, ALICE BARINOTTI3, simone baldovino2, ELISA MENEGATTI4 and Dario Roccatello5, 1University of Turin, Torino, Italy, 2University Center of Excellence on Nephrologic, Rheumatologic and Rare Diseases (ERK-net, ERN-Reconnect and RITA-ERN Member) with Nephrology and Dialysis Unit and Center of Immuno-Rheumatology and Rare Diseases (CMID), Coordinating Center of the Interregional Network for Rare Diseases of Piedmont and Aosta Valley, San Giovanni Bosco Hub Hospital, Turin, Italy, 3University Center of Excellence on Nephrologic, Rheumatologic and Rare Diseases (ERK-Net, ERN-Reconnect and RITA-ERN Member) with Nephrology and Dialysis Unit and Center of Immuno-Rheumatology and Rare Diseases (CMID), Coordinating Center of the Interregional Network for Rare Diseases of Piedmont and Aosta Valley, Department of Clinical and Biological Sciences, University of Turin, Turin, Italy, 4School of Specialization of Clinical Pathology, Department of Clinical and Biological Sciences, University of Turin, Turin, Italy, 5University of Torino, Torino, Italy

    Background/Purpose: Patients on B-cell depleting agents may have a suboptimal response to vaccination, placing them at a higher risk of contracting SARS-CoV-2 or suffering from…
  • Abstract Number: 1856 • ACR Convergence 2023

    Improving Recombinant Zoster Vaccination Rates in Patients Receiving Immunosuppressive Therapy in the Rheumatology Clinic at the Orlando VA Healthcare System – a Quality Improvement Project

    Kathlyn Camargo Macias1, Ravi Shahu Khal1, Ariail Schmitz2, Kathleen McCabe1, Taylor Kann1, Marilyn Mosquera3 and Ashwini Komarla4, 1University of Central Florida, Orlando, FL, 2University of Central Florida, St. Cloud, FL, 3University of Central Florida, Casselberry, FL, 4ORLANDO VAMC, Orlando, FL

    Background/Purpose: Herpes zoster is a painful rash that involves one to three adjacent dermatomes, secondary to reactivation of latent varicella-zoster virus (VZV). About 95 %…
  • Abstract Number: 0616 • ACR Convergence 2023

    Does Systemic Sclerosis Affect the Interpretation of Mammograms? A Retrospective Cohort Study

    Lea Meir1, Tegveer Sandhu2, Weiwei Chi2 and Gabriela Santiago2, 1Icahn School of Medicine, New York, NY, 2Icahn School of Medicine at Mount Sinai, New York, NY

    Background/Purpose: Systemic Sclerosis is an autoimmune disorder marked by thickened and hardened skin. Cutaneous cutis, the deposition of insoluble calcium salts in the skin and…
  • Abstract Number: 1895 • ACR Convergence 2023

    Comparative Analysis of Existing Tools in Assessing Cardiovascular Risk in Patients with Rheumatoid Arthritis: Exploring the Inadequacies

    Pritee Shrestha1, Peter Larsen1 and Pablo Weilg Espejo2, 1Mercy One North Iowa Medical Center, Mason City, IA, 2Boston Medical Center, Chelsea, MA

    Background/Purpose: Patients with Rheumatoid Arthritis (RA) are at increased risk of cardiovascular disease (CVD). Despite multiple CVD risk tools available, reliability to RA population is…
  • Abstract Number: 0742 • ACR Convergence 2023

    Risk of Incident Gout Associated with Initiation of Sodium-glucose cotransporter-2 Inhibitors versus Other Second-line Agents Among Metformin Users with Type 2 Diabetes

    Natalie McCormick1, Chio Yokose2, Na Lu3 and Hyon K. Choi4, 1Massachusetts General Hospital, Boston, MA, 2Massachusetts General Hospital, Waltham, MA, 3Arthritis Research Canada, Vancouver, BC, Canada, 4Massachusetts General Hospital and Harvard Medical School, Lexington, MA

    Background/Purpose: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are a revolutionary second-line treatment for type 2 diabetes associated with lower risk of cardiovascular and all-cause mortality, heart failure,…
  • Abstract Number: 1935 • ACR Convergence 2023

    Pre-exposure Prophylaxis with Tixegvimab/cilgavimab Is Effective in Limiting the Risk and Severity of COVID-19 in Patients with Auto Immune or Inflammatory Diseases at Increased Risk of Severe COVID-19

    Marion THOMAS1, Maeva MASSON2, Raphaele Seror3, Samuel Bitoun4, Henry DUPUY5, Lazato ESTIBALIZ5, Christophe Richez6, Yannick ALLANORE7 and Jerome AVOUAC8, 1HOPITAL COCHIN AP-HP, Service de Rhumatologie, Paris, France, 2CHU Toulouse, Toulouse, France, 3University Hospital Paris Saclay, Le Kremlin-Bicêtre, France, 4CHU Bicêtre APHP, Le Kremlin-Bicêtre, France, 5CHU Bordeaux, Bordeaux, France, 6Université de Bordeaux, Bordeaux, France, 7Université Paris Cité, Paris, France, 8Rheumatology A Department, Hôpital Cochin, AP-HP Centre - Université Paris Cité, Paris, France

    Background/Purpose: Patients with autoimmune or inflammatory diseases treated with immunosuppressants such as anti-CD20 are at increased risk for severe COVID-19 and have a high probability…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 12
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology